Sold as Votrient. Every FDA application for this active ingredient: 1 branded and 6 generic. Boxed warning
As of Nov 21, 2026, FDA lists 7 applications for Pazopanib hydrochloride (sold as Votrient), first approved Oct 19, 2009, with 3 new uses approved and 0 published complete response letters.
| Oct 19, 2009 | VotrientNDA 22465 · New molecular entity | Novartis Pharmaceuticals | 28 | Marketed |
| Oct 19, 2023 | Pazopanib HydrochlorideANDA 215837 | Sun Pharmaceutical Industries | 1 | Marketed |
| Oct 19, 2023 | Pazopanib HydrochlorideANDA 217517 | Teva Pharmaceuticals | 0 | Marketed |
| Oct 19, 2023 | Pazopanib HydrochlorideANDA 217713 | Apotex | 1 | Marketed |
| Apr 23, 2024 | Pazopanib HydrochlorideANDA 218231 | Novugen | 0 | Marketed |
| Dec 4, 2024 | Pazopanib HydrochlorideANDA 219034 | Eugia Pharma | 0 | Marketed |
| Sep 4, 2025 | Pazopanib HydrochlorideANDA 219922 | Torrent Pharmaceuticals | 1 | Marketed |
| Pazopanib HCl | Part D | $45.9M | +10% | 1,733 |
| Votrient | Part D | $7.2M | −67% | 153 |
Of the 72 whose ending is known, 40% met their primary endpoint, 14% missed it and 46% stopped early.
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaMetastatic Sarcoma, Recurrent Sarcoma · M.D. Anderson Cancer Center | Not applicable | Recruiting | Dec 13, 2019 |
| Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid TumorsForegut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor · National Cancer Institute (NCI) | Phase 2 | Active, not recruiting | Apr 26, 2013 |
| Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney CancerClear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer · Roswell Park Cancer Institute | Phase 1 / Phase 2 | Active, not recruiting | Sep 13, 2012 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryClear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7 · National Cancer Institute (NCI) | Phase 3 | Active, not recruiting | Apr 11, 2012 |
| Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid TumorsSolid Neoplasm · National Cancer Institute (NCI) | Phase 1 | Active, not recruiting | Mar 13, 2012 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA